CBZ-L-Arginine, formally N_α-[(benzyloxy)carbonyl]-L-arginine, is catalogued under the model designation CBZ-L-Arg-OH and is distinguished from its methyl ester, tert-butyl ester, and side-chain-protected derivatives by the combination of a free terminal carboxyl and an unprotected guanidine. The CAS registry number is 1234-35-1, the molecular formula is C₁₄H₂₀N₄O₄, and the molecular weight is 308.33 g/mol. The benzyloxycarbonyl group, abbreviated Cbz or Z, is introduced through benzyl chloroformate and provides N_α protection that is stable to piperidine and trifluoroacetic acid but labile to catalytic hydrogenation and hydrogen bromide in acetic acid. This profile places the product in solution-phase peptide synthesis, C-terminal activation of arginine fragments, and convergent route design. HPLC purity is commonly ≥98.0%, water content is ≤0.5%, and residual solvents are reported under USP <467>. The material is an intermediate; it is not intended for direct pharmaceutical formulation.

Industrial lots are prepared by benzyloxycarbonylation of L-arginine under alkaline aqueous conditions. Process impurities include benzyl alcohol, dibenzyl carbonate, and the N_α,N_ω-bis-protected derivative; these are controlled by headspace gas chromatography and HPLC. Residual benzyl alcohol is typically limited to ≤1000 ppm because it can act as a competing nucleophile during carbodiimide activation and generate undesired benzyl esters. Vacuum drying at 40 °C to 50 °C is used before sieving through a 60 mesh screen to reduce bulk density variation in automated dispensing systems.

What Processing Constraints Arise from the Unprotected Guanidine Function?

The unprotected guanidine side chain of CBZ-L-Arg-OH has a pK_a of 12.48 for the conjugate acid and remains predominantly protonated in neutral DMF or dichloromethane. This protonation does not completely eliminate nucleophilic reactivity at the N_ω position. Under carbodiimide activation, the free guanidine can intercept the O-acylisourea to form an N_ω-acylated adduct or cyclise to the five-membered lactam. The ratio of desired peptide coupling to guanidine acylation is concentration-dependent, and process-scale batch records from jacketed glass reactors indicate that substrate concentrations above 0.5 mol/L increase the proportion of N_ω-modified impurity when measured by HPLC area per cent at 206 nm.

Typical activation protocols use dicyclohexylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide with 1-hydroxybenzotriazole in DMF at 0.2 mol/L to 0.3 mol/L and a jacket temperature of 0 °C to 5 °C for 30 min to 45 min before addition of the amine component. HOBt addition at 1.0 to 1.05 equivalents relative to the carboxyl accelerates conversion of the O-acylisourea to the less aggressive HOBt ester and reduces racemization. Residual dicyclohexylurea from DCC-mediated reactions is removed by filtration through a 0.45 µm PTFE membrane before aqueous workup because the urea coprecipitates with product from cold solvent. For EDC-mediated couplings, the water-soluble urea is removed by ethyl acetate–water partition at pH 3 to 4 with citric acid; the guanidine remains protonated at this pH and the Cbz-protected product partitions into the organic phase.

Process-scale failure modes include incomplete activation from adventitious water and formation of a gel phase when the free guanidine is neutralised during aqueous workup at pH above 7. The gel reduces phase separation and product recovery. Centrifugal partition or back-extraction with saturated sodium chloride is used to break emulsified layers. Because the guanidine can retain counterions from hydrochloride or acetate salts, elemental analysis of counterion content and ion chromatography for chloride are included in some technical data packages; residual chloride is controlled to ≤0.5% when the product is destined for base-sensitive coupling routes.

Racemization is monitored by chiral HPLC or by derivatising the crude dipeptide with a chiral derivatising agent; residual D-Arg diastereomer is typically rejected at ≤0.5%. If the coupling temperature exceeds 10 °C during diisopropylcarbodiimide activation, oxazolone formation from the activated carboxyl increases. Addition of N,N-diisopropylethylamine above 1.1 equivalents increases the risk of N_ω-functionalisation because the guanidine is partially deprotonated at pH above 8.5.

Analytical release criteria for the peptide synthesis grade are given in Table 1. The specification is intended for intermediate use, not for direct formulation; residual solvent levels should be re-verified for GMP campaigns according to USP <467> and ICH Q3C, while residual metals are measured by ICP-MS against an internal limit derived from the route of manufacture.

HPLC peak shape for CBZ-L-Arg-OH depends strongly on mobile-phase counterion. With 0.1% trifluoroacetic acid and an acetonitrile gradient on a 5 µm C18 column, the protonated guanidine elutes as a single peak with retention time reproducible within ±0.2 min. When neutral phosphate buffer is used, peak tailing can obscure the D-enantiomer; therefore chiral purity is measured separately on a chiral stationary phase with UV detection at 210 nm. Loss on drying at 105 °C for 2 h is used for release, but Karl Fischer titration is more specific for water in acetate-containing lots. Residue on ignition ≤0.1% by USP <281> is relevant for routes using palladium-catalysed hydrogenolysis, where inorganic residues can interfere with final peptide crystallisation.

The Absence of a Side-Chain Protecting Group Distinguishes CBZ-L-Arg-OH from Fmoc-Arg(Pbf)-OH in Solid-Phase Workflows

Fmoc-SPPS routes typically use Fmoc-L-Arg(Pbf)-OH because the 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl group blocks the guanidine and prevents the same N_ω-acylation side reaction observed with CBZ-L-Arg-OH. The Pbf group is removed by trifluoroacetic acid cleavage cocktails after chain assembly, while the Fmoc group is removed by piperidine during each cycle. CBZ-L-Arg-OH lacks the acid-labile sulfonyl protection, so it is not a direct replacement for Fmoc-L-Arg(Pbf)-OH in iterative solid-phase chain extension. It is instead used at the terminal arginine position, where the Cbz group serves as the final N_α cap and is removed by hydrogenolysis after cleavage from the resin. The Cbz group survives 20% piperidine in DMF for 20 min at 20 °C to 25 °C; therefore a CBZ-Arg-containing fragment can be coupled to an Fmoc-deprotected resin without damaging the Cbz group.

For solid-phase coupling of CBZ-L-Arg-OH, carbodiimide activation with HOBt or Oxyma is performed in DMF or NMP at a resin substitution between 0.2 mmol/g and 0.4 mmol/g. Coupling efficiency is monitored by the Kaiser test or bromophenol blue, and a double coupling at 25 °C for 30 min is often used because the unprotected guanidine can reduce effective activator concentration. The product is more difficult to couple onto hindered N-methyl amino acids than Fmoc-L-Arg(Pbf)-OH; steric hindrance from the free guanidine and the benzyloxycarbonyl group lowers the initial coupling rate. Table 2 summarises the route-relevant differences.

Under acidic N_α-Boc removal conditions, the Cbz group is largely retained, whereas the Boc group is cleaved within minutes by 95% trifluoroacetic acid in dichloromethane. This selectivity enables convergent solution-phase assembly in which a Boc-protected side chain is deprotected without exposing the N-terminal Cbz of an arginine fragment. Conversely, Cbz removal is achieved by catalytic hydrogenation over 5% to 10% palladium on carbon at hydrogen pressures of 0.1 MPa to 0.4 MPa, or by transfer hydrogenation with ammonium formate. The free guanidine can coordinate palladium and reduce catalyst activity; increasing catalyst mass to 0.1 to 0.2 equivalents per mole of substrate is sometimes required for complete cleavage. Hydrogenation is performed in methanol or ethanol–water mixtures at 20 °C to 40 °C, but the solvent choice must be validated when the target peptide contains hydrogenation-sensitive functions such as thioethers, thiols, halides, or conjugated alkenes.

At pilot scale, hydrogenolysis is conducted in glass-lined pressure vessels or stainless steel autoclaves rated for 0.6 MPa to 1.0 MPa working pressure. Catalyst loss through sintered filters is a documented source of palladium contamination; a second filtration through a 0.22 µm membrane followed by treatment with a metal scavenger such as trimercaptotriazine on silica reduces palladium content below 10 ppm by ICP-MS. The reaction vessel is sparged with nitrogen before hydrogen introduction, and the headspace hydrogen concentration is maintained below 4% in air to avoid flammability.

When Hydrogenolysis Is Incompatible with the Target Peptide, Alternative N_α Protection Must Be Selected

If the final peptide or peptidomimetic contains methionine, cysteine, or olefinic side chains, catalytic hydrogenation of the Cbz group can generate off-target reduction products. Under these conditions, the N_α-protection strategy is shifted to Fmoc-L-Arg(Pbf)-OH or Boc-L-Arg-OH, although Boc-L-Arg-OH retains the same free guanidine side-reaction risk as CBZ-L-Arg-OH and therefore requires the same low-temperature HOBt or HOAt activation. The selection of CBZ-L-Arg-OH over unprotected L-arginine is justified primarily by the need to control N_α selectivity during C-terminal activation; with unprotected L-arginine, the α-amino group is acylated under basic conditions, producing oligomers and racemised by-products. CBZ-L-Arg-OH allows C-terminal ester, amide, or hydrazide activation while the N_α position remains blocked, and the guanidine may be selectively derivatized later if required.

C-terminal activation of CBZ-L-Arg-OH to the p-nitroanilide has been scaled in 20 L glass reactors by converting the carboxylic acid to the N-hydroxysuccinimide ester with EDC and N-hydroxysuccinimide in DMF at 0 °C to 5 °C for 4 h. The resulting activated ester is reacted with p-nitroaniline in the presence of N-methylmorpholine to produce CBZ-L-Arg-pNA, a chromogenic derivative used in protease activity assays. The intermediate ester is moisture-sensitive and is not isolated; conversion is monitored by disappearance of the acid spot on TLC and by HPLC at 254 nm after derivatisation. Similar activation is used to prepare peptide fragments and hydrazides for convergent assembly. In all cases, the free guanidine can be temporarily protonated with HCl to suppress nucleophilic interception; residual HCl is removed before coupling to base-labile linkers.

CBZ-L-Arg-OH is hygroscopic and should be stored in tightly closed containers under inert gas at 2 °C to 8 °C. Handling in open air above 60% relative humidity increases water uptake and can reduce apparent purity by forming hydrates; pre-drying and Karl Fischer verification are required before kilogram-scale coupling operations. The material is incompatible with strong reducing agents, strong oxidising agents, and strong aqueous acids under storage conditions. Residual palladium from hydrogenolysis must be controlled in downstream peptide purification by scavenger treatment or repeated filtration; typical specifications for palladium in peptide intermediates are below 10 ppm by ICP-MS. The product is not designed for direct injection or oral administration and must be converted to the unprotected peptide or amino acid before any pharmacological or toxicological evaluation.